Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.
Published:
Does Insurance Cover GLP-1 for Insulin Resistance? (2026)
By The RX Index Editorial Team · Last verified: May 23, 2026
The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers.
The honest answer: usually no, not for insulin resistance alone. Insurance plans almost never pay for a GLP-1 medication when the only reason on the chart is “insulin resistance.” But here’s the part that matters — a lot of people searching this question have a different truthful path sitting in their chart already. Type 2 diabetes, prediabetes with the right BMI, obesity, sleep apnea with obesity, or established cardiovascular disease. Each is a real covered path. This guide explains which one fits your chart.
This guide pulls insurer coverage rules, the CMS Medicare GLP-1 Bridge criteria (live July 1, 2026), Medicaid state policy, and the prior authorization documentation most doctors’ offices fumble — into one place.
Quick Verdict — Find Yourself in This Table
| If this is you | Coverage odds | Where to start |
|---|---|---|
| Insulin resistance only, normal A1C, BMI under 27 | Low | Talk to your doctor about what other diagnosis your chart actually supports |
| Prediabetes (A1C 5.7–6.4%) + BMI 27 or higher | Possible — new Medicare Bridge path opens July 1, 2026 | Check coverage; see the Medicare Bridge path below |
| Type 2 diabetes diagnosis | Strong | The diabetes path is the cleanest — most plans cover Ozempic, Mounjaro with prior auth |
| BMI 30 or higher | Possible if plan covers weight-management drugs | Wegovy, Zepbound, or Foundayo path |
| BMI 27–29.9 + hypertension, high cholesterol, sleep apnea, or other comorbidity | Moderate, plan-dependent | The “overweight plus comorbidity” path |
| PCOS + obesity | Moderate; PCOS alone is harder | Combine PCOS with obesity coding |
| On Medicare Part D and eligible for the GLP-1 Bridge | New as of July 1, 2026 — possible at $50/month | Use the Bridge process directly, not a commercial telehealth concierge |
| On Medicaid | State-dependent — only 13 state fee-for-service programs cover GLP-1s for obesity | Check your state’s formulary first |
| Employer plan excludes weight-loss meds | Low through obesity route | Look for a T2D, OSA, or cardiovascular path, or compare cash-pay |
| Already denied | Depends on the denial reason | Read the denial letter carefully before resubmitting |
Check what your plan actually covers — free
If your row above looks like a real coverage path, the fastest free first step is Ro Body (sponsored affiliate link, opens in a new tab)’s GLP-1 Insurance Coverage Checker. It contacts your insurer, runs the coverage and prior-auth check, and sends you a personalized report — what’s covered, your copay estimate, and what the PA needs. Best for commercial insurance.
Check My GLP-1 Coverage on Ro — Free → (sponsored affiliate link, opens in a new tab)(sponsored)Does Insurance Cover GLP-1 for Insulin Resistance? The Honest Answer
Usually not. Insurance plans anchor GLP-1 prior authorization to FDA-approved indications, formulary rules, and plan exclusions — not to insulin resistance by itself. No GLP-1 on the market has FDA approval for “insulin resistance” as its own condition. Coverage almost always requires a paired diagnosis that is on the FDA label.
Insulin resistance, prediabetes, and type 2 diabetes are not the same thing
These three terms get used interchangeably in everyday conversation, but they’re different to your insurance company.
Insulin resistance
Your body doesn’t respond well to insulin; your pancreas pumps out more to compensate. ICD-10-CM codes: E88.819 (insulin resistance, unspecified) and E88.810 (metabolic syndrome). Having a code doesn’t mean a GLP-1 is covered for that indication.
Prediabetes
Blood sugar above normal but below the diabetes line. NIDDK defines it as A1C 5.7%–6.4%, fasting plasma glucose 100–125 mg/dL, or OGTT 140–199 mg/dL. Code: R73.03. Rarely covered alone under standard Part D or commercial, but a real new path opens July 1, 2026 under the Medicare Bridge.
Type 2 diabetes — where coverage opens
NIDDK diagnostic thresholds: A1C ≥6.5%, fasting glucose ≥126 mg/dL, 2-hour OGTT ≥200 mg/dL, or random glucose ≥200 mg/dL with symptoms. T2D codes (E11.x) get GLP-1s covered on nearly every plan with prior authorization.
Why insurers anchor to the FDA label
Every PA policy traces back to the FDA-approved use on the medication label. Insurers do this for three reasons:
- It’s defensible. A coverage decision that follows the FDA label is hard to challenge.
- It controls cost. GLP-1s run $900–$1,400/month at retail. Insurers can’t sustainably pay for off-label use at that price.
- It limits scope. Insulin resistance affects a meaningful share of American adults. Covering it alone would have an enormous budget impact.
Cigna’s own PA policy says it directly: GLP-1/GIP agonists “are not indicated in a patient with elevated blood glucose who does not have type 2 diabetes,” and the same policy says they are not indicated for metabolic syndrome without type 2 diabetes either.
The “safe coding” rule — don’t ask your doctor to lie
Do not ask a clinician to code a diagnosis you don’t actually have. It’s insurance fraud, it can backfire on the doctor’s license, and it can void your coverage if discovered. The right move is to identify a truthful coverage path that fits your real chart. That’s what the rest of this page is for.
The Five Legitimate Coverage Paths in 2026
Insurance won’t pay for a GLP-1 because you have insulin resistance. But it will often pay if your chart shows one of five specific situations. Your job (and your doctor’s) is to identify the right one truthfully.
Path 1 — Type 2 Diabetes (the strongest coverage path)
If your A1C has hit 6.5% on two readings, or your fasting glucose is 126 mg/dL or higher, you may meet the criteria for type 2 diabetes. This is the cleanest GLP-1 coverage path on virtually every commercial plan, Medicare Part D, and Medicaid.
- What’s covered: Ozempic (T2D + cardiovascular/kidney-risk uses), Mounjaro (T2D and pediatric 10+), Rybelsus, Trulicity
- What’s typically required: Confirmed T2D (ICD-10 E11.x), A1C history, sometimes prior metformin trial (step therapy)
Path 2 — Prediabetes + BMI 27+ (the brand-new Medicare Bridge path)
Starting July 1, 2026, the Medicare GLP-1 Bridge covers Wegovy, Foundayo, and the Zepbound KwikPen for $50/month for eligible Medicare Part D beneficiaries. Bridge runs through December 31, 2027.
To qualify under Tier 3, your prescriber must attest that you have:
- BMI 27 or higher, AND
- Prediabetes (A1C 5.7–6.4% per ADA guidelines), previous heart attack, previous stroke, or symptomatic peripheral artery disease
This matters for insulin-resistance patients because many with chronic insulin resistance progress to prediabetes long before full diabetes. Before July 2026, Medicare gave that population nothing. Now there’s a real path.
Read the full Medicare GLP-1 Bridge guide →Path 3 — Obesity (BMI 30 or higher)
The cleanest commercial path. If your BMI is 30+ and your insurance plan includes weight-management drug coverage, you likely qualify for Wegovy, Zepbound, or Foundayo with prior authorization. Adult obesity coding may use E66.811, E66.812, E66.813, or E66.01 — paired with the appropriate Z68 BMI code. The catch: only a share of commercial plans cover GLP-1s for weight loss; some explicitly exclude. Your plan documents control this.
Path 4 — BMI 27–29.9 with a Recognized Comorbidity
This is the path that helps the most insulin-resistance readers, because insulin resistance almost always travels with at least one of these:
If you have insulin resistance plus any of these, that combination — not insulin resistance alone — unlocks the door. Your PA should lead with the comorbidity and the BMI, with insulin resistance as supporting context.
Path 5 — PCOS with Obesity
PCOS as a standalone reason rarely gets approved (it’s still off-label). But PCOS + BMI 30+ often does, coded primarily as obesity with PCOS as a related condition. A high proportion of women with PCOS also have insulin resistance, so this path is highly relevant.
Read the dedicated GLP-1 for PCOS insurance guide →The Full Coverage Matrix
Every row is tied to a primary source listed in the verification column. Verified May 23, 2026.
Specific plan documents control. Self-funded ERISA plans may have entirely different coverage. Always verify with your plan’s specific formulary.
| Your situation | Coverage likelihood | Best medication path | What the insurer is really looking for | Best next action |
|---|---|---|---|---|
| Insulin resistance only, normal A1C, BMI under 27 | Low | No clean FDA-approved coverage path | A covered diagnosis, not just “insulin resistance” | Ask your doctor what other diagnosis your chart supports |
| Prediabetes, BMI under 27 | Low on most commercial plans | Usually no GLP-1 coverage unless another condition exists | FDA-approved indication or plan-specific criteria | Check formulary; explore metformin first |
| BMI ≥27 + prediabetes, hypertension, dyslipidemia, OSA, CVD, NAFLD, or PCOS | Moderate (if plan covers weight-management GLP-1s) | Wegovy, Zepbound, Foundayo, Saxenda | BMI, comorbidity proof, lifestyle program, formulary | Run a coverage check; submit PA with BMI + comorbidity |
| BMI ≥30 + plan covers weight-management drugs | Moderate to strong, still PA-dependent | Wegovy, Zepbound, Foundayo | BMI documentation, lifestyle attempts, formulary status | Check plan, then choose a PA-support provider |
| BMI ≥30 but employer plan excludes weight-loss drugs | Low through obesity route | Maybe T2D, OSA, or CV path if chart supports it | Whether the benefit is excluded entirely | Read plan documents — exclusions can’t be appealed |
| Type 2 diabetes diagnosis | Higher than IR alone | Ozempic, Mounjaro, Rybelsus, Trulicity | Diabetes diagnosis, A1C history, step therapy | Ask about diabetes-indicated GLP-1 with PA |
| Established CVD + overweight or obesity | Possible via Wegovy CV indication | Wegovy | CVD documentation + BMI + plan rules | Ask if the CV path is cleaner than the weight-loss path |
| Moderate-to-severe OSA + obesity | Possible via Zepbound OSA indication | Zepbound | Sleep study, OSA severity, BMI | Ask whether OSA is the cleanest route |
| Medicare Part D + Bridge-eligible | Possible starting July 1, 2026 | Foundayo, Wegovy (all formulations), Zepbound KwikPen only | CMS Bridge criteria + PA via central processor | Use the Bridge process; don’t try to use a commercial concierge |
| Medicaid | State-dependent (13 states cover obesity GLP-1s) | State formulary + in-network clinician | State-specific rules | Check your state formulary first |
| Denied for insulin resistance | Depends on denial reason | Appeal, resubmit with new path, or cash-pay | Exclusion vs. documentation gap vs. wrong diagnosis | Read the denial letter before doing anything else |
Not sure which row fits you?
Take our free 60-second matching quiz. Tell us your situation — insurance type, BMI, A1C, conditions, denial history — and we’ll generate your personalized next-step checklist.
Take the Free 60-Second Quiz →What Major Insurers Actually Say About Insulin Resistance
No major U.S. payer covers insulin resistance as a standalone reason for a GLP-1 in 2026. Each has its own list of qualifying conditions that do unlock coverage.
Blue Cross Blue Shield (varies by affiliate)
BCBS isn’t one company. It’s a federation of 33 independent affiliates, each setting its own coverage policies. As plans renew throughout 2026, many BCBS affiliates have cut weight-loss GLP-1 coverage for small-group and direct-pay members. Critical distinction: if your BCBS plan has a benefit exclusion for weight-loss GLP-1s (as BCBS Massachusetts confirmed for some 2026 members), there is no appeal path. That’s different from a prior-auth denial, which you can appeal.
Source: BCBS Massachusetts GLP-1 coverage update notice. Verified May 2026.
Cigna
Cigna’s published prior authorization policy is the most explicit: GLP-1 agonists “are not indicated in a patient with elevated blood glucose who does not have type 2 diabetes,” and the same policy notes they are not indicated for metabolic syndrome without type 2 diabetes. For commercial Cigna plans with weight-management coverage, criteria typically include BMI 30+ or BMI 27+ with a weight-related comorbidity, plus structured lifestyle intervention documented.
Source: Cigna Coverage Policy CNF360 — Glucagon-Like Peptide-1 Agonists Prior Authorization. Verified May 2026.
Aetna
Aetna’s public Wegovy prior-authorization example shows how coverage can work when the plan includes the weight-management benefit: PA criteria require BMI 30+ or BMI 27 with a weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia — along with documentation of a comprehensive weight-management program.
Source: Aetna Wegovy PA documentation (Pharmacy Clinical Policy Bulletin). Verified May 2026.
UnitedHealthcare / OptumRx
UHC/OptumRx prior-authorization criteria vary by plan. UHC’s public weight-loss PA materials reference conditions including hypertension, dyslipidemia, sleep apnea, cardiovascular disease, type 2 diabetes, NAFLD/MASH, PCOS, and osteoarthritis. PCOS being recognized in some UHC plans matters for women with insulin resistance + PCOS — that combination has a direct path on those plans.
Source: UnitedHealthcare/OptumRx public weight-loss PA documentation. Verified May 2026.
Mass General Brigham Health Plan (employer-exclusion example)
As of January 1, 2026, Mass General Brigham Health Plan stopped covering GLP-1s with obesity/weight-management indications for individual commercial members and small employers. Coverage for type 2 diabetes use continues. This is representative of the carve-out trend hitting commercial insurance across the country.
Source: Mass General Brigham Health Plan GLP-1 coverage page.
Medicare Part D + the New GLP-1 Bridge
Standard Medicare Part D: Covers GLP-1s for T2D broadly, Wegovy for CV risk reduction (established CVD + obesity/overweight), and Zepbound for moderate-to-severe OSA with obesity. Does not cover GLP-1s for insulin resistance or weight loss alone.
Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027): $50/month copay at pharmacy. Three eligibility tiers:
| Tier | Criteria |
|---|---|
| Tier 1 | BMI 35 or higher, no additional condition required |
| Tier 2 | BMI 30+ plus uncontrolled hypertension (on 2+ medications), CKD stage 3a or higher, or heart failure |
| Tier 3 | BMI 27+ plus prediabetes (A1C 5.7–6.4% per ADA), prior MI, prior stroke, or symptomatic peripheral artery disease |
BMI and qualifying conditions are evaluated at the time of initiating GLP-1 therapy. The Bridge covers all formulations of Foundayo and Wegovy and only the Zepbound KwikPen formulation. CMS says paper claims and direct member reimbursements are not accepted through the central processor — do not pay cash expecting Bridge reimbursement later.
Source: CMS Medicare GLP-1 Bridge page (last modified May 12, 2026; product list updated April 6, 2026).
On Medicare and Bridge-eligible? Don’t try to route through a commercial telehealth membership — Ro and most other concierges can’t coordinate Bridge coverage. Use your existing prescriber or a Medicare-accepting obesity provider set up for the Bridge process.
Read the Medicare GLP-1 Bridge guide →Medicaid
State-by-state and complicated. Only 13 state Medicaid fee-for-service programs covered GLP-1s for obesity treatment as of January 2026, per KFF. California, New Hampshire, Pennsylvania, and South Carolina eliminated weight-loss coverage. Most states cover GLP-1s broadly for type 2 diabetes. Insulin resistance is not a covered Medicaid indication in any state we’ve reviewed.
See 50-state Medicaid GLP-1 tracker →The Prior Authorization Checklist Your Doctor Should Follow
Many avoidable GLP-1 denials happen when the PA is submitted under the wrong indication or without the documentation the plan requires. Verify against your specific plan’s published criteria.
Common PA documentation checklist
- Current BMI documentation (some plans require more than one measurement; confirm timing rules with your insurer)
- Primary indication ICD-10 code (E66.811/E66.812/E66.813 or E66.01 for obesity, E11.x for T2D, R73.03 for prediabetes — paired correctly)
- Supporting comorbidity codes as applicable (E88.819 for insulin resistance, E88.810 for metabolic syndrome, I10 for hypertension, E78.x for dyslipidemia, G47.33 for sleep apnea, E28.2 for PCOS)
- Recent labs: A1C, fasting glucose, comprehensive metabolic panel, lipid panel, TSH (to rule out thyroid causes of weight gain), pregnancy test for women of childbearing age
- Documented prior attempts at weight management — many plans expect 3–6 months of structured lifestyle intervention with dates and outcomes
- Letter of medical necessity from your prescriber, explaining treatment goals, expected outcomes, and the rationale for GLP-1 specifically
- Prior medications tried (especially metformin if diabetes or prediabetes is involved)
The “don’t waste the PA” question to ask your prescriber
Before your doctor submits the prior auth, ask: “Which medication and indication are we submitting under?” This single question prevents the most common error — trying to get Ozempic covered for off-label insulin resistance when your chart actually supports a weight-management medication like Wegovy under the obesity-plus-comorbidity path.
ICD-10 routing reference
Documentation literacy, not medical advice. Your prescriber decides what’s clinically true.
| Code | What it codes | Used alone for GLP-1 PA? | Use it as… |
|---|---|---|---|
| E88.819 | Insulin resistance, unspecified | Rarely accepted as standalone | Supporting context, not the primary GLP-1 coverage path |
| E88.810 | Metabolic syndrome | Rarely accepted as standalone | Pair only when clinically true with obesity, prediabetes, T2D, or another covered path |
| R73.03 | Prediabetes | Rarely covered alone under standard Part D or commercial | Pair with BMI 27+ for the Medicare Bridge; or with obesity codes for some commercial plans |
| E11.9 / E11.x | Type 2 diabetes | Yes — broadly covered for diabetes-indicated GLP-1s with PA | Stands alone |
| E66.811 / E66.812 / E66.813 | Adult obesity, class 1 / 2 / 3 | Yes, on plans that cover weight-management GLP-1s when PA criteria are met | Pair with the appropriate Z68 BMI code and any required comorbidity/lifestyle documentation |
| E66.01 | Severe obesity due to excess calories | Yes, on plans that cover weight-management GLP-1s when clinically documented | Pair with Z68 BMI code |
| E66.9 | Obesity, unspecified | Sometimes; plans often want specificity | Pair with BMI code and comorbidities |
| Z68.30–Z68.45 | Adult BMI codes | Required as a supporting code with E66 | Always pair with E66 |
| E28.2 | Polycystic ovarian syndrome | Rarely sufficient alone (off-label) | Pair with E66 (obesity) for the strongest commercial path |
The Insurer Call Script — What to Ask Before You Submit Anything
“Do you cover GLP-1s?” gets you a useless answer. “Do you cover this specific medication for this specific diagnosis on my plan?” gets you what you actually need. Read this to the rep word for word:
“Hi, I want to ask about coverage for [Wegovy / Zepbound / Ozempic / Mounjaro / Foundayo].”
- Is it on my formulary?
- What tier is it?
- Is it covered for [your diagnosis]?
- Is prior authorization required?
- Does my plan have a benefit exclusion for weight-management medications?
- Does coverage differ for diabetes vs. obesity vs. obstructive sleep apnea vs. cardiovascular risk?
- Is step therapy required — do I need to try metformin or other meds first?
- What BMI is required?
- What labs are required?
- Is a supervised lifestyle program required, and for how long?
- Is there a quantity limit?
- Can you fax or email the prior-authorization criteria to my prescriber?
- What’s the appeal process if denied?
- What’s the external review process?
#12 — getting the criteria sent to your prescriber — is the most useful item on the list. It means your doctor’s office has the exact PA checklist your insurer uses before they submit.
What to Do If You’re Already Denied
A denial isn’t always the end. An appeal can work when the denial was caused by missing documentation, step therapy, a diagnosis mismatch, or formulary preference — but it usually won’t fix a true benefit exclusion. The right next move depends entirely on why you were denied.
Denial reason #1 — Benefit exclusion
If your employer plan or insurance plan has a benefit exclusion for weight-management medications, no appeal will overturn it. This is a plan-design decision, not a clinical one. BCBS Massachusetts has confirmed this explicitly for their excluded plans. Stop appealing. Move to a covered indication if your chart supports one (T2D, OSA, or CV risk), check whether your employer offers a different plan option, or compare FDA-approved cash-pay options.
Denial reason #2 — Wrong diagnosis path
If your PA was filed under “insulin resistance” alone, this is often the cause. Talk to your doctor about whether another diagnosis your chart already supports — obesity with comorbidity, prediabetes with BMI 27+, PCOS with obesity — is a stronger PA route. This isn’t about changing what’s true; it’s about leading with the right truth.
Denial reason #3 — Missing documentation
The chart didn’t have what the insurer wanted. Common gaps: insufficient BMI documentation, A1C older than the plan accepts, no documentation of prior lifestyle intervention, no step therapy proof, no formal comorbidity diagnosis (just symptoms). Ask your doctor’s office what was on the PA form and what was missing. Resubmit with the gaps closed.
Denial reason #4 — Wrong medication for your plan
Sometimes the plan prefers Wegovy over Zepbound, or a diabetes-indicated GLP-1 over a weight-loss one. Switching to the preferred medication is often faster than fighting for the non-preferred one.
How to file an appeal
- Internal appeal (Level 1): typically 30–60 days. Written request with a letter of medical necessity from your prescriber.
- Peer-to-peer review: your doctor calls a clinical reviewer at the insurance company. Often the fastest way to overturn a denial.
- External / independent review: if Level 1 fails, you can request an outside reviewer.
- State insurance commissioner: for unresolved disputes.
What to put in the letter of medical necessity
- Your diagnoses with ICD-10 codes
- BMI and weight trajectory
- Documented insulin resistance (HOMA-IR, fasting insulin, OGTT if available)
- A1C trend over time
- Prior weight-management attempts (dates, methods, outcomes)
- Comorbidities and how a GLP-1 addresses them
- Why a GLP-1 specifically (vs. metformin or other options)
- The clinical urgency (preventing progression to T2D, addressing CV risk)
Already denied and not sure what comes next?
Take our free 60-second matching quiz. We’ll generate a personalized next-step checklist based on your specific denial reason.
Build My Next-Step Checklist →Should You Use Ro for This?
For most commercial-insurance readers, yes. Ro Body (sponsored affiliate link, opens in a new tab)’s free GLP-1 Insurance Coverage Checker is the cleanest first action — it contacts your insurer, runs the coverage and prior-auth check, and tells you what’s covered and at what copay. For Medicare and Medicaid readers, Ro is not the right first step, and we’ll explain why.
Why Ro fits this query specifically
- The Coverage Checker is free. No signup, no payment, no medical visit required. Upload your insurance card; Ro contacts your insurer and sends a personalized report.
- Ro carries FDA-approved GLP-1s — Foundayo (FDA-approved April 1, 2026), Wegovy pill, Wegovy pen, Zepbound pen, and Zepbound KwikPen. Pricing matches LillyDirect, NovoCare, and TrumpRx for the medication itself.
- Their insurance concierge handles the PA paperwork. This is the boring grind most patients lose to. Ro’s team does it as part of the membership.
In Ro’s 2025 GLP-1 Insurance Coverage Checker Report, 43% of users had GLP-1 coverage for weight loss, and among covered patients, half had a copay of $50/month or less.
The damaging admission you need to know
Ro’s Body membership is cash-pay, even if your medication is covered. You’d pay $39 for the first month, then $149/month ongoing, or as low as $74/month if you prepay annually. Insurance might cover the medication itself at a low copay; you’d still pay the Ro membership separately.
If that’s a dealbreaker, an in-network telehealth provider (or your regular doctor’s office) might be the better fit — your visits would be billed to insurance, no separate membership cost.
When Ro is NOT the right first step
- Medicare, Medicare supplement, or TRICARE: Ro can’t help coordinate GLP-1 coverage for government insurance plans. Medicare and TRICARE users may be able to join Ro Body and pay out of pocket for certain cash-pay options, but the insurance concierge doesn’t apply.
- Medicaid and most government-funded plans: You can’t join Ro Body or pay out of pocket through Ro. Use your state’s network.
- FEHB is Ro’s stated exception for insurance-concierge support.
- You have a confirmed plan exclusion: Save the step and go straight to the cash-pay comparison below.
Run the free coverage check before your PA is submitted
If you have commercial insurance and your situation looks like a qualifying path, the highest-leverage free action you can take is the Ro Coverage Checker.
Check My GLP-1 Coverage on Ro — Free → (sponsored affiliate link, opens in a new tab)(sponsored)What If Insurance Still Won’t Pay — Cash-Pay Options Worth Considering
If your plan won’t cover a GLP-1 even with the right paperwork, FDA-approved cash-pay options now exist that didn’t a year ago.
FDA-approved cash-pay comparison (verified May 2026)
| Option | What it covers | Verified pricing | Best for |
|---|---|---|---|
| Ro Body | Foundayo, Wegovy pill, Wegovy pen, Zepbound pen, Zepbound KwikPen | Membership $39 first month, then $149/month ongoing, or as low as $74/month with annual prepay; medication billed separately at LillyDirect / NovoCare / TrumpRx parity | Cash-pay shoppers who want ongoing clinical care plus a broad FDA-approved menu |
| Sesame Care (Success by Sesame) | Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo, Saxenda | Subscription from $59/month. Wegovy pill from $149/month, Zepbound KwikPen from $299/month, Wegovy pen $199/month first two months then $349/month, Foundayo from $149/month | Cash-pay shoppers who want maximum brand choice |
| LillyDirect (Zepbound Self Pay Journey) | Zepbound single-dose vials | From $299/month (2.5 mg), $399/month (5 mg), $449/month (other approved doses); no provider care included | Patients who already have a prescriber and want Lilly’s medication direct |
| NovoCare | Wegovy pill and Wegovy injection | Wegovy pill from $149/month for 1.5 mg and 4 mg (limited time); Wegovy injection $199/month first two fills of 0.25 mg and 0.5 mg through June 30, 2026, then $349/month | Patients with a Wegovy prescription who want to pay direct |
A note on HSA and FSA
HSA/FSA administrators may allow reimbursement from your own tax-advantaged account for eligible prescription expenses. That’s not the same as insurance coverage — it’s reimbursement from your own pre-tax money. IRS Publication 969 confirms that HSA distributions used for qualified medical expenses aren’t taxed. Verify with your account administrator before assuming a specific medication or membership fee will qualify.
A compliance note on compounded GLP-1s
After the FDA determined the semaglutide injection product shortage was resolved on February 21, 2025, shortage-based access to compounded semaglutide tightened. Compounded GLP-1 medications are not FDA-approved finished products. Evaluate compounded programs as a separate cash-pay decision, not as an insurance workaround.
How We Verified This Guide
For this guide, we reviewed coverage rules from major insurers, CMS Medicare GLP-1 Bridge guidance, Medicaid policy research from KFF, FDA medication approvals, and prior authorization criteria documents.
Primary sources
- FDA prescribing information for Wegovy, Zepbound, Ozempic, Mounjaro, and Foundayo (approved April 1, 2026)
- NIDDK definitions for insulin resistance, prediabetes, and type 2 diabetes
- Wegovy cardiovascular risk indication: FDA press release
- Zepbound OSA indication: FDA press release
- Cigna Coverage Policy CNF360 (GLP-1 Agonists Prior Authorization)
- Aetna Wegovy PA documentation (Pharmacy Clinical Policy Bulletin)
- BCBS Massachusetts GLP-1 coverage update notice
- Mass General Brigham Health Plan GLP-1 page
- UnitedHealthcare/OptumRx public weight-loss PA documentation
- CMS Medicare GLP-1 Bridge page (last modified May 12, 2026; product list updated April 6, 2026)
- KFF Medicaid coverage of GLP-1s tracker (January 2026)
- FDA statement on compounded GLP-1 supply following the resolved semaglutide shortage
- Ro public pricing page, insurance page, and 2025 Coverage Checker Report
- LillyDirect Zepbound Self Pay Journey pricing: Eli Lilly investor announcement
- NovoCare Wegovy pricing: NovoCare pharmacy page
- Sesame Care online weight loss program page
- IRS Publication 969
Last verified: May 23, 2026. This page is refreshed monthly during 2026 because of the Medicare GLP-1 Bridge launch and ongoing payer policy changes. Next refresh: June 23, 2026, or sooner if CMS, FDA, or a major payer publishes a material change.
Frequently Asked Questions
Does insurance cover GLP-1 for insulin resistance?
Usually not for insulin resistance alone. Insulin resistance isn't an FDA-approved indication for any GLP-1 medication, and no major U.S. insurer covers it on that basis by itself. Coverage typically requires a paired diagnosis — type 2 diabetes (the strongest path), obesity, overweight with a recognized comorbidity, established cardiovascular disease, obstructive sleep apnea with obesity, or for Medicare beneficiaries starting July 1, 2026, the new GLP-1 Bridge program.
Is insulin resistance enough to get Ozempic covered?
No. Ozempic is FDA-approved for adults with type 2 diabetes for glycemic control and certain cardiovascular and kidney-risk uses — not for insulin resistance. Coverage for Ozempic without a T2D diagnosis is rare and typically requires a separate covered indication.
Can I get a GLP-1 covered without diabetes?
Yes, but not for insulin resistance alone. You can get a GLP-1 covered without diabetes if your chart truthfully supports an obesity diagnosis (BMI ≥30), overweight with a recognized comorbidity (BMI ≥27 plus hypertension, dyslipidemia, sleep apnea, cardiovascular disease, or PCOS on some plans), cardiovascular disease with overweight or obesity (Wegovy path), or moderate-to-severe sleep apnea with obesity (Zepbound path).
Does insurance cover Wegovy for prediabetes?
Standard commercial coverage rarely approves Wegovy for prediabetes alone. But starting July 1, 2026, the Medicare GLP-1 Bridge program covers Wegovy at $50/month for beneficiaries with BMI 27+ plus prediabetes (A1C 5.7–6.4% per ADA guidelines). For commercial insurance, prediabetes plus BMI 27 plus another recognized comorbidity is more likely to be approved than prediabetes alone.
Does PCOS help get a GLP-1 covered?
PCOS alone usually doesn't unlock coverage because it's off-label use. PCOS plus obesity (BMI 30+) often does. Some UnitedHealthcare plans recognize PCOS as a comorbidity for women with insulin resistance and PCOS, but coverage still depends on your specific plan policy.
What A1C qualifies for type 2 diabetes coverage?
NIDDK lists the diabetes diagnostic thresholds as A1C 6.5% or higher, fasting plasma glucose 126 mg/dL or higher, 2-hour OGTT 200 mg/dL or higher, or random plasma glucose 200 mg/dL or higher when symptoms are present. Once T2D is documented with ICD-10 code E11.x, GLP-1 coverage is broadly available across most commercial plans, Medicare Part D, and Medicaid.
What BMI do insurers require for GLP-1 coverage?
For obesity-indicated GLP-1s, most insurers require BMI 30 or higher, or BMI 27–29.9 plus a recognized comorbidity. Plans typically want BMI documented within a specific recent window. The Medicare GLP-1 Bridge starts at BMI 27 with qualifying conditions, BMI 30 with others, or BMI 35 alone.
How long does GLP-1 prior authorization take?
Most commercial plans process complete PAs in 2 to 5 business days when submitted electronically. Incomplete documentation is the most common cause of delays beyond that. Denials trigger an appeals process that typically takes 30 to 60 days for Level 1 review.
What if my employer plan excludes weight-loss drugs?
A benefit exclusion is different from a prior-authorization denial. Exclusions are plan-design decisions and cannot be appealed. If your plan has an exclusion, your remaining paths are: a covered indication if your chart truthfully supports one (T2D, OSA, CV risk), switching plans during open enrollment, or FDA-approved cash-pay routes like Ro, Sesame, LillyDirect, or NovoCare.
Does Medicare cover GLP-1s for insulin resistance?
Standard Medicare Part D does not cover GLP-1s for insulin resistance. It covers them for type 2 diabetes broadly, Wegovy for cardiovascular risk reduction with established CVD and obesity or overweight, and Zepbound for moderate-to-severe sleep apnea with obesity. The Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) is the first Medicare coverage of GLP-1s for obesity directly, with eligibility tied to BMI and qualifying conditions.
Does Medicaid cover GLP-1s for insulin resistance?
Most state Medicaid programs do not cover GLP-1s for insulin resistance or for weight loss alone. Only 13 state fee-for-service programs cover GLP-1s for obesity as of January 2026, per KFF, typically with utilization controls. Type 2 diabetes coverage is broadly available across nearly all states.
Can I use HSA or FSA funds if insurance denies coverage?
Yes, in most cases. GLP-1 medications prescribed by a licensed physician for an eligible medical condition are typically HSA- and FSA-eligible expenses, even when paid out of pocket. This isn't insurance coverage — it's reimbursement from your own tax-advantaged account. Verify with your HSA or FSA administrator; some require itemized receipts and a letter of medical necessity.
Are compounded GLP-1s covered by insurance?
Generally no. Compounded GLP-1 medications are not FDA-approved finished products. They are not reviewed by the FDA for safety, effectiveness, or quality the way FDA-approved drugs are. Insurance plans don't cover them.
Should I use Ro or my primary care doctor to handle this?
Ro is the more efficient route for most commercial-insurance patients because their team runs the GLP-1 PA workflow daily and includes an insurance concierge. The trade-off is that Ro's Body membership is cash-pay even when your medication is covered. Your primary care doctor doesn't carry that separate cost, but execution varies. If you're on Medicare, TRICARE, or Medicaid, work with your in-network clinic rather than Ro.
What should I do after a denial?
Read the denial letter first. The reason determines the right next step — appealing makes sense for documentation gaps but is wasted on benefit exclusions. If the denial reason is a documentation gap, work with your prescriber to close the gap and resubmit. If the reason is a wrong diagnosis path, talk to your doctor about whether another truthful indication fits your chart. If the denial is a benefit exclusion, move to cash-pay or a different plan at open enrollment.
Still not sure which path is yours?
Tell us your situation — your specific plan, BMI, A1C, conditions, and prior history. We’ll generate a personalized action plan with the most likely coverage path, the right documentation checklist, and the next step that fits you.
No card, no commitment. Ro link is sponsored.
Related guides on The RX Index
- Does Insurance Cover GLP-1 for PCOS?
- GLP-1 Providers That Accept Insurance for Insulin Resistance
- Medicare GLP-1 Bridge: $50/mo Through December 2027
- Medicaid GLP-1 Coverage by State: 50-State Tracker
- GLP-1 Cost Without Insurance: What You’ll Actually Pay
- Best GLP-1 Providers That Accept Insurance (2026)
- Can I Use HSA for GLP-1?
Affiliate disclosure: The RX Index earns commission when readers sign up with some providers we cover, including Ro and Sesame Care. Affiliate relationships never determine our editorial conclusions. Coverage policy facts come first.
Medical disclaimer: This guide is for educational purposes only. It is not medical advice and does not replace consultation with a licensed clinician. Insurance coverage decisions are made by your plan, not by us.
Editorial standards: We do not include “medically reviewed by” attributions unless a credentialed clinician has reviewed the page in writing. We do not invent author credentials.
Last verified: May 23, 2026 · Next scheduled review: June 23, 2026